ClinicalTrials.gg
CompletedNCT00720057Updated Aug 25, 2015Results posted

Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.

A Phase 3 interventional study of Naproxen Sodium ER (BAYH6689) and Placebo in Toothache, sponsored by Bayer. Completed at 3 sites in United States. Open to participants aged 16 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-25.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
16 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 55 studies in Toothache with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Toothache · United States.

Enrollment
9th of 51
312 · median 193
Started
2008
with 2 others
Phase 3
11 of 55
none open now
Registered
7th of 55
by date
Lead sponsor
5 of 55
Bayer

Among the 55 studies in Toothache with a site in United States, this one is the 9th largest by enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2008, is one of 11 in phase 3, and was the 7th registered.

Toothache

143 studies on the registry are indexed under Toothache; 29 are open to participants now.

Browse Toothache studies →

Open to participants now

7 of the 55 studies in Toothache with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Toothache studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.

This study: 16 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Toothache with a site in United States, or all of them as a file.
02

Study summary

To evaluate the analgesic efficacy of a single, oral dose of a naproxen sodium extended-release tablet, compared to placebo in postsurgical dental pain.

03

Conditions studied

  • Toothache

Browse trials for

Keywords

  • Dental Pain
  • Analgesia
04

Who can participate

Ages eligible
16 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, ambulatory, male and female volunteers between 16 to 45
  • Scheduled to undergo surgical removal of 1 - 2 impacted third molars, one of which must be at least a partial mandibular bony impaction
  • No use of any analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, any other pain reliever (Over The Counter or prescription), or herbal supplements within 5 days of surgery
  • Have moderate to severe postoperative pain on the Categorical Pain Intensity Scale (a score of at least 2 on a 4 point scale) and a score of >/= 50 mm on the 100-mm visual analog Pain Severity Rating Scale

Exclusion criteria

Exclusion Criteria:

  • History of to naproxen sodium, aspirin (ASA), other NSAIDs, opioid analgesics, and similar pharmacological agents or components of the products, including the placebo
  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or
  • Relevant concomitant disease such as asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than 50 percent obstruction (polyposis nasi, marked septal deviation) that can interfere with the conduct of the study
  • Current or past history of bleeding disorder(s)
  • History of gastrointestinal bleeding or perforation, related to previous NSAID therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
312 participants (actual)

Study arms

  • Experimental
    Naproxen sodium ER (BAYH6689)

    single dose (1 tablet) ER Naproxen sodium 660 mg with a full glass of water (240ml) within 1 - 4 hours post dental surgery.

    Drug: Naproxen Sodium ER (BAYH6689)

  • Placebo comparator
    Placebo

    Single dose (1 tablet) of placebo with a full glass of water (240ml) within 1 - 4 hours post dental surgery.

    Drug: Placebo

Interventions

  • DrugNaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Analgesic efficacy in dental pain; per oral; 1 tablet extended release Naproxen Sodium; with a full glass of water within 4 hours post surgery

  • DrugPlacebo

    Inactive ingredient; per oral; 1 lactose based tablet; with a full glass of water within 4 hours post surgery

06

What researchers measure

Primary outcomes

  1. Summed Pain Intensity Difference (SPID)

    Categorical pain intensity scale - no pain (0), mild pain (1), moderate pain (2), or severe pain (3) was used for all pain intensity assessments postdose. Time-weighted Sum Pain Intensity Difference (SPID) was calculated by multiplying the Pain Intensity Difference (PID) score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values over 0-24 and 16-24 hours, respectively.

    Time frame: 0 to 24 hours post dose

Secondary outcomes

  1. Total Pain Relief (TOTPAR)

    Pain relief categorical rating scale - no relief (0), a little relief (1), some relief (2), a lot of relief (3), or complete relief (4) was used for all pain relief assessments postdose. Time weighted total pain relief (TOTPAR) was calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values.

    Time frame: 0-24 hours post dose

  2. Summed Pain Intensity Difference at Specific Time Intervals

    Categorical pain intensity scale - no pain (0), mild pain (1), moderate pain (2), or severe pain (3) was used for all pain intensity assessments postdose. Time-weighted Sum Pain Intensity Difference (SPID) was calculated by multiplying the Pain Intensity Difference (PID) score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values for 0-6, 0-12, 0-16 hour intervals, respectively.

    Time frame: 0-16 hours post dose

  3. Time to First Use of Rescue Medication

    Time to first use of rescue medication was estimated using the Kaplan-Meier method and analyzed by a Log rank test stratified by trial site and baseline pain intensity (PI). The outcome measure is time to first use of rescue medication. The criteria are if adequate pain relief is not achieved, then subjects are permitted to take rescue medication.

    Time frame: postdose to first use of rescue medication

  4. Global Assessment of the Investigational Product as a Pain Reliever

    Categorical Scale: Poor (0), Fair (1), Good (2), Very Good (3), Excellent (4).

    Time frame: at 24 hours postdose or immediately before first use of rescue medication

  5. Time to Onset of Effect

    Time to onset of effect is defined as the time to meaningful pain relief, provided that the subjects experienced both "perceptible" and "meaningful" pain relief. Perceptible pain relief was defined as when the subject first began to feel any pain-relieving effect from the investigational product. Meaningful pain relief was defined as when the subject felt the degree of pain relief was meaningful to them.

    Time frame: from postdose to onset of first perceptible and meaningful pain relief for up to 6 hours

07

Results

Posted Jan 25, 2011

Participant flow

Participant flow — Overall Study
MilestoneNaproxen Sodium ER (BAYH6689)Placebo
Started153159
Completed152156
Not completed13
Withdrew: Lost to follow-up02
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject01

Outcome measures

PrimarySummed Pain Intensity Difference (SPID)

Categorical pain intensity scale - no pain (0), mild pain (1), moderate pain (2), or severe pain (3) was used for all pain intensity assessments postdose. Time-weighted Sum Pain Intensity Difference (SPID) was calculated by multiplying the Pain Intensity Difference (PID) score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values over 0-24 and 16-24 hours, respectively.

Time frame:
0 to 24 hours post dose
Reported as:
Mean · units on a scale
Summed Pain Intensity Difference (SPID)
units on a scaleNaproxen Sodium ER (BAYH6689)Placebo
SPID 0-2425.9 ± 25.87-3.1 ± 18.40
SPID16-248.8 ± 9.30-1.0 ± 6.89
Statistical analysis
  • Naproxen Sodium ER (BAYH6689) vs Placebo · ANCOVA · p = <0.001
SecondaryTotal Pain Relief (TOTPAR)

Pain relief categorical rating scale - no relief (0), a little relief (1), some relief (2), a lot of relief (3), or complete relief (4) was used for all pain relief assessments postdose. Time weighted total pain relief (TOTPAR) was calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values.

Time frame:
0-24 hours post dose
Reported as:
Mean · units on a scale
Total Pain Relief (TOTPAR)
units on a scaleNaproxen Sodium ER (BAYH6689)Placebo
TOTPAR 0 - 6 hours12.7 ± 7.813.1 ± 5.07
TOTPAR 0 - 12 hours25.5 ± 17.065.5 ± 10.70
TOTPAR 0 - 16 hours34.1 ± 23.497.2 ± 14.83
TOTPAR 0 - 24 hours51.3 ± 36.4110.9 ± 23.95
TOTPAR 16 - 24 hours17.2 ± 13.373.7 ± 9.40
Statistical analysis
  • Naproxen Sodium ER (BAYH6689) vs Placebo · ANCOVA · p = <0.001
SecondarySummed Pain Intensity Difference at Specific Time Intervals

Categorical pain intensity scale - no pain (0), mild pain (1), moderate pain (2), or severe pain (3) was used for all pain intensity assessments postdose. Time-weighted Sum Pain Intensity Difference (SPID) was calculated by multiplying the Pain Intensity Difference (PID) score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values for 0-6, 0-12, 0-16 hour intervals, respectively.

Time frame:
0-16 hours post dose
Reported as:
Mean · units on a scale
Summed Pain Intensity Difference at Specific Time Intervals
units on a scaleNaproxen Sodium ER (BAYH6689)Placebo
SPID 0 - 66.2 ± 5.7-0.4 ± 4.2
SIPD 0 - 1212.7 ± 12.3-1.4 ± 8.54
SIPD 0 - 1617.1 ± 16.85-2.0 ± 11.68
Statistical analysis
  • Naproxen Sodium ER (BAYH6689) vs Placebo · ANCOVA · p = <0.001
SecondaryTime to First Use of Rescue Medication

Time to first use of rescue medication was estimated using the Kaplan-Meier method and analyzed by a Log rank test stratified by trial site and baseline pain intensity (PI). The outcome measure is time to first use of rescue medication. The criteria are if adequate pain relief is not achieved, then subjects are permitted to take rescue medication.

Time frame:
postdose to first use of rescue medication
Reported as:
Median · hours
Time to First Use of Rescue Medication
hoursNaproxen Sodium ER (BAYH6689)Placebo
Time to First Use of Rescue Medication22.27 (1.07 to 22.27)1.90 (1.03 to 10.12)
Statistical analysis
  • Naproxen Sodium ER (BAYH6689) vs Placebo · Log Rank · p = <0.001
SecondaryGlobal Assessment of the Investigational Product as a Pain Reliever

Categorical Scale: Poor (0), Fair (1), Good (2), Very Good (3), Excellent (4).

Time frame:
at 24 hours postdose or immediately before first use of rescue medication
Reported as:
Mean · units on a scale
Global Assessment of the Investigational Product as a Pain Reliever
units on a scaleNaproxen Sodium ER (BAYH6689)Placebo
Global Assessment of the Investigational Product as a Pain Reliever2.3 ± 1.430.6 ± 1.04
Statistical analysis
  • Naproxen Sodium ER (BAYH6689) vs Placebo · Cochran-Mantel-Haenszel · p = <0.001
SecondaryTime to Onset of Effect

Time to onset of effect is defined as the time to meaningful pain relief, provided that the subjects experienced both "perceptible" and "meaningful" pain relief. Perceptible pain relief was defined as when the subject first began to feel any pain-relieving effect from the investigational product. Meaningful pain relief was defined as when the subject felt the degree of pain relief was meaningful to them.

Time frame:
from postdose to onset of first perceptible and meaningful pain relief for up to 6 hours
Reported as:
Median · hours
Time to Onset of Effect
hoursNaproxen Sodium ER (BAYH6689)Placebo
Time to Onset of Effect1.37 (0.07 to 4.98)4.13 (0.07 to 4.75)
Statistical analysis
  • Naproxen Sodium ER (BAYH6689) vs Placebo · Log Rank · p = <0.001

Adverse events

Collected over Adverse events were recorded throughout the treatment period through 5 days after investigational product or placebo administration. All Serious Adverse Events were collected through about 30 days after the last dose of investigational product or placebo.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Naproxen Sodium ER (BAYH6689)—0/153 (0%)10/153 (6.5%)
Placebo—0/159 (0%)36/159 (22.6%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventNaproxen Sodium ER (BAYH6689)Placebo
NauseaGastrointestinal disorders3/15324/159
VomitingGastrointestinal disorders2/15314/159
DizzinessNervous system disorders1/1538/159
HeadacheNervous system disorders5/1536/159
Tooth Socket HaemorrhageGastrointestinal disorders1/1532/159
Eye SwellingEye disorders1/1530/159
PyrexiaGeneral disorders1/1530/159
Abscess OralInfections and infestations1/1530/159
SyncopeNervous system disorders1/1531/159
Pharyngolaryngeal PainRespiratory, thoracic and mediastinal disorders1/1530/159

Baseline characteristics

Age, Continuous
Age, Continuous(years)Naproxen Sodium ER (BAYH6689)PlaceboTotal
Mean20.8 ± 4.0320.4 ± 4.3120.6 ± 4.17
Sex: Female, Male
Sex: Female, Male(Participants)Naproxen Sodium ER (BAYH6689)PlaceboTotal
Female89106195
Male6453117
Baseline Pain Intensity by Categorical Scale
Baseline Pain Intensity by Categorical Scale(participants)Naproxen Sodium ER (BAYH6689)PlaceboTotal
Moderate99103202
Severe5456110
Baseline Pain Intensity by Visual Analog Scale
Baseline Pain Intensity by Visual Analog Scale(scores on a scale)Naproxen Sodium ER (BAYH6689)PlaceboTotal
Mean72.3 ± 13.1372.6 ± 11.9172.4 ± 12.51
08

Study locations

3 sites
  • Austin, Texas 78705, United States
  • Austin, Texas 78744, United States
  • Salt Lake City, Utah 84124, United States
09

References and documents

Publications

  • Laurora I, An R. Efficacy of single-dose, extended-release naproxen sodium 660 mg in postsurgical dental pain: two double-blind, randomized, placebo-controlled trials. Curr Med Res Opin. 2016;32(2):331-42. doi: 10.1185/03007995.2015.1123680. Epub 2015 Dec 15. Erratum In: Curr Med Res Opin. 2016;32(3):611. doi: 10.1185/03007995.2016.1148233. PubMed 26588111 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 2 years 5 months after primary completion. A results delay was requested in Dec 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2008
First posted
Jul 22, 2008
Start
Jun 2008
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results delay requested
Dec 9, 2009
Results first posted
Jan 25, 2011
Last update
Aug 25, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00720057
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 22, 2008
Start date
Jun 2008
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Jan 25, 2011
Last update
Aug 25, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naproxen

Start the discussion